+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Acquired Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 146 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5641382
According to the National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Medical practitioners warn that acquired hemophilia can cause life-threatening bleeding complications in severe cases. In around 50% of cases, there is an identifiable underlying clinical condition; in the other 50%, no cause is known i.e. it is idiopathic. The acquired hemophilia treatment market is anticipated to grow at a CAGR of 3.25% during the forecast period of 2022-2030.

Rise in Geriatric Population Remains as The Key Driver

Acquired hemophilia is caused by autoantibody formation to FVIII4. The incidence rate of the condition is 0.2 to 1.48 cases per million individuals per year. Considering the sexes, acquired hemophilia affects both males and females equally. However, the incidence of this condition appears greater in older adults over 65 years of age. In such a population, bleeding episodes may be severe, difficult to control, and fatal in some cases. The incidence of acquired hemophilia A in individuals aged 65 years is 0.28 patients per million per year, but increases to 5.97 in ages between 65 to 85 years and reduces to 16.6 in individuals older than 85 years. Overall, more than 80% of diagnosed cases are aged 60 years. These data are believed to be likely underestimated because of the chances of undiagnosed and unreported cases.

Traditional Therapies Continue to Dominate to the Market

The types of traditional therapies used to treat acquired hemophilia are steroid treatment, cytotoxic therapy, and immunomodulatory therapy. The advanced treatments segmentation includes recombinant activated factor VII/NovoSeven RT, recombinant porcine factor VIII, activated prothrombin complex concentrate (aPCC)/FEIBA, and desmopressin (DDAVP). Though traditional therapies dominate the market in 2021, advanced therapies are expected to take up their share significantly during the forecast period. The advanced therapies are proving their efficiency across the globe, resulting in increased uptake.

Hospitals Remain as The Key Healthcare Setting for Therapy

Hospitals remain as the key healthcare setting due to availability of broad range of therapeutic options. Additionally, the availability of registered medical practitioners along with reimbursement policies make hospitals most preferable healthcare setting for management and treatment of hemophilia. Clinics are expected to grow fastest during the forecast period as they are cost effective and less complex in comparison to hospitals.

APAC Promises Opportunities During the Forecast Period

After scrutiny of the global acquired hemophilia treatment market, the regional trends, market sizes, and the overall growth paired with the latest and anticipated events, North America is observed to be the most dominant regional market for acquired hemophilia treatment. However, Asia Pacific promises significant opportunities during the forecast period, growing at the highest CAGR of 5.97% from 2022-2030.

Focus on Product Pipeline Remains the Key Focus Among Market Players

The global acquired hemophilia treatment market is observed as a diversified and competitive market comprising a large number of players. The spearheading market players include Roche, Sanofi, Pfizer, Baxter, Takeda, CSL Behring; Novo Nordisk A/S; and others. The major market participants implemented growth strategies such as partnerships, new product launches, and operational expansion to gain a competitive advantage. The top most strategy followed by top competitors includes trial announcements. Key companies such as Pfizer, F. Hoffman LA Roche, Sanofi, Genentech Inc and Novo Nordisk are actively involved in product trials placed for approvals.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. Key data points that enables the estimation of Acquired Hemophilia Treatment market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Acquired Hemophilia Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Acquired Hemophilia Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Acquired Hemophilia Treatment market?
  • Which is the largest regional market for Acquired Hemophilia Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Acquired Hemophilia Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Acquired Hemophilia Treatment market worldwide?

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Acquired Hemophilia Treatment Market
2.2. Global Acquired Hemophilia Treatment Market, By Type, 2021 (US$ Million)
2.3. Global Acquired Hemophilia Treatment Market, By Treatment, 2021 (US$ Million)
2.4. Global Acquired Hemophilia Treatment Market, By Therapeutic Areas, 2021 (US$ Million)
2.5. Global Acquired Hemophilia Treatment Market, By End-User, 2021 (US$ Million)
2.6. Global Acquired Hemophilia Treatment Market, By Geography, 2021 (US$ Million)
2.7. Global Acquired Hemophilia Treatment Market, By Impact of COVID-19, 2020 (US$ Million)
2.8. Key Investment Proposition by Geography, 2021
2.9. Competitive Analysis
2.10. Key Industry Strategies
2.11. Tier Analysis 2021 Versus 2030
2.12. Key Buying Criteria
2.13. Key Case Reports
2.14. Scenario Analysis
2.15. Optimistic estimates and analysis
2.16. Realistic estimates and analysis
2.17. Pessimistic estimates and analysis
2.18. Market Profiling
2.19. Sales and Marketing Plan
2.20. Heptalysis Analysis
2.21. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions
2.22. Top Market Conclusions
2.23. Strategic Recommendations
3. Acquired Hemophilia Treatment Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Acquired Hemophilia Treatment Market Value, 2020-2030, (US$ Million)
3.3. Key Trends Analysis
3.4. Market Dynamics
3.4.1. Market Drivers
3.4.2. Market Restraints
3.4.3. Key Challenges
3.4.4. Key Opportunities
3.5. Impact Analysis of Drivers and Restraints
3.6. See-Saw Analysis
3.7. Attractive Investment Proposition
3.8. Porter’s Five Force Model
3.8.1. Supplier Power
3.8.2. Buyer Power
3.8.3. Threat Of Substitutes
3.8.4. Threat Of New Entrants
3.8.5. Competitive Rivalry
3.9. PESTEL Analysis
3.9.1. Political Landscape
3.9.2. Economic Landscape
3.9.3. Technology Landscape
3.9.4. Legal Landscape
3.9.5. Social Landscape
3.10. Competitive Landscape
3.10.1. Market Positioning of Key Acquired Hemophilia Treatment Market Vendors
3.10.2. Strategies Adopted by Acquired Hemophilia Treatment Market Vendors
4. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Hemophilia A
4.3.2. Hemophilia B
4.3.3. Hemophilia C
4.3.4. Others
5. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. On-Demand
5.3.2. Prophylaxis
6. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Replacement Therapy
6.3.2. Gene Therapy
6.3.3. Immune Tolerance Induction Therapy
6.3.4. Others
7. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2021 Versus 2030
7.3. Market Segmentation
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Others
8. North America Acquired Hemophilia Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
8.3. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
8.5. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
8.6.Acquired Hemophilia Treatment Market: By Region, 2020-2030, USD (Million)
8.6.1.North America
8.6.1.1. U.S.
8.6.1.1.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
8.6.1.1.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
8.6.1.1.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
8.6.1.1.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
8.6.1.2. Canada
8.6.1.2.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
8.6.1.2.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
8.6.1.2.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
8.6.1.2.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
8.6.1.3. Rest of North America
8.6.1.3.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
8.6.1.3.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
8.6.1.3.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
8.6.1.3.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
9. UK and European Union Acquired Hemophilia Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
9.3. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
9.5. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
9.6.Acquired Hemophilia Treatment Market: By Region, 2020-2030, USD (Million)
9.6.1.UK and European Union
9.6.1.1. UK
9.6.1.1.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
9.6.1.1.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
9.6.1.1.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
9.6.1.1.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
9.6.1.2. Germany
9.6.1.2.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
9.6.1.2.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
9.6.1.2.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
9.6.1.2.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
9.6.1.3. Spain
9.6.1.3.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
9.6.1.3.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
9.6.1.3.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
9.6.1.3.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
9.6.1.4. Italy
9.6.1.4.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
9.6.1.4.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
9.6.1.4.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
9.6.1.4.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
9.6.1.5. France
9.6.1.5.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
9.6.1.5.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
9.6.1.5.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
9.6.1.5.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
9.6.1.6. Rest of Europe
9.6.1.6.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
9.6.1.6.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
9.6.1.6.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
9.6.1.6.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
10. Asia Pacific Acquired Hemophilia Treatment Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
10.3. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
10.4. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
10.5. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
10.6.Acquired Hemophilia Treatment Market: By Region, 2020-2030, USD (Million)
10.6.1.Asia Pacific
10.6.1.1. China
10.6.1.1.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
10.6.1.1.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
10.6.1.1.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
10.6.1.1.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
10.6.1.2. Japan
10.6.1.2.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
10.6.1.2.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
10.6.1.2.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
10.6.1.2.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
10.6.1.3. India
10.6.1.3.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
10.6.1.3.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
10.6.1.3.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
10.6.1.3.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
10.6.1.4. Australia
10.6.1.4.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
10.6.1.4.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
10.6.1.4.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
10.6.1.4.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
10.6.1.5. South Korea
10.6.1.5.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
10.6.1.5.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
10.6.1.5.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
10.6.1.5.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
10.6.1.6. Rest of Asia Pacific
10.6.1.6.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
10.6.1.6.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
10.6.1.6.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
10.6.1.6.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
11. Latin America Acquired Hemophilia Treatment Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
11.3. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
11.4. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
11.5. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
11.6.Acquired Hemophilia Treatment Market: By Region, 2020-2030, USD (Million)
11.6.1.Latin America
11.6.1.1. Brazil
11.6.1.1.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
11.6.1.1.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
11.6.1.1.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
11.6.1.1.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
11.6.1.2. Mexico
11.6.1.2.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
11.6.1.2.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
11.6.1.2.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
11.6.1.2.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
11.6.1.3. Rest of Latin America
11.6.1.3.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
11.6.1.3.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
11.6.1.3.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
11.6.1.3.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
12. Middle East and Africa Acquired Hemophilia Treatment Market, 2020-2030, USD (Million)
12.1. Market Overview
12.2. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
12.3. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
12.4. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
12.5. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
12.6.Acquired Hemophilia Treatment Market: By Region, 2020-2030, USD (Million)
12.6.1.Middle East and Africa
12.6.1.1. GCC
12.6.1.1.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
12.6.1.1.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
12.6.1.1.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
12.6.1.1.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
12.6.1.2. Africa
12.6.1.2.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
12.6.1.2.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
12.6.1.2.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
12.6.1.2.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
12.6.1.3. Rest of Middle East and Africa
12.6.1.3.1. Acquired Hemophilia Treatment Market: By Type, 2020-2030, USD (Million)
12.6.1.3.2. Acquired Hemophilia Treatment Market: By Treatment, 2020-2030, USD (Million)
12.6.1.3.3. Acquired Hemophilia Treatment Market: By Therapeutic Areas, 2020-2030, USD (Million)
12.6.1.3.4. Acquired Hemophilia Treatment Market: By End-User, 2020-2030, USD (Million)
13. Company Profile
13.1. Baxter Healthcare Corporation
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Portfolio
13.1.4. Strategic Initiatives
13.2. Biogen
13.2.1. Company Overview
13.2.2. Financial Performance
13.2.3. Product Portfolio
13.2.4. Strategic Initiatives
13.3. Pfizer
13.3.1. Company Overview
13.3.2. Financial Performance
13.3.3. Product Portfolio
13.3.4. Strategic Initiatives
13.4. F. HOFFMAN LA ROCHE
13.4.1. Company Overview
13.4.2. Financial Performance
13.4.3. Product Portfolio
13.4.4. Strategic Initiatives
13.5. Sanofi
13.5.1. Company Overview
13.5.2. Financial Performance
13.5.3. Product Portfolio
13.5.4. Strategic Initiatives
13.6. Ferring Pharmaceuticals
13.6.1. Company Overview
13.6.2. Financial Performance
13.6.3. Product Portfolio
13.6.4. Strategic Initiatives
13.7. Genentech, Inc.
13.7.1. Company Overview
13.7.2. Financial Performance
13.7.3. Product Portfolio
13.7.4. Strategic Initiatives
13.8. Bristol Myers Squibb
13.8.1. Company Overview
13.8.2. Financial Performance
13.8.3. Product Portfolio
13.8.4. Strategic Initiatives
13.9. Novo Nordisk
13.9.1. Company Overview
13.9.2. Financial Performance
13.9.3. Product Portfolio
13.9.4. Strategic Initiatives
13.10. GlaxoSmithKline plc
13.10.1. Company Overview
13.10.2. Financial Performance
13.10.3. Product Portfolio
13.10.4. Strategic Initiatives
13.11. Takeda Pharmaceutical
13.11.1. Company Overview
13.11.2. Financial Performance
13.11.3. Product Portfolio
13.11.4. Strategic Initiatives
13.12. CSL Behring
13.12.1. Company Overview
13.12.2. Financial Performance
13.12.3. Product Portfolio
13.12.4. Strategic Initiatives
13.13. Bayer AG
13.13.1. Company Overview
13.13.2. Financial Performance
13.13.3. Product Portfolio
13.13.4. Strategic Initiatives
List of Figures
Figure 1 Global Acquired Hemophilia Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Acquired Hemophilia Treatment Market: Quality Assurance
Figure 5 Global Acquired Hemophilia Treatment Market, By Type, 2021
Figure 6 Global Acquired Hemophilia Treatment Market, By Treatment, 2021
Figure 7 Global Acquired Hemophilia Treatment Market, By Therapeutic Areas, 2021
Figure 8 Global Acquired Hemophilia Treatment Market, By End-User, 2021
Figure 9 Global Acquired Hemophilia Treatment Market, By Geography, 2021
Figure 10 Market Geographical Opportunity Matrix - Global Acquired Hemophilia Treatment Market, 2021
Figure 11 Market Positioning of Key Acquired Hemophilia Treatment Market Players, 2021
Figure 12 Global Acquired Hemophilia Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 13 Porters Five Force Model - Current, Midterm and Long Term Perspective
Figure 14 See Saw Analysis
Figure 15 PETEL Analysis
Figure 16 Key Buying Criteria: Current and Long-Term Perspective
Figure 17 Global Acquired Hemophilia Treatment Market, Scenario Analysis, 2020 to 2030 (US$ Million)
Figure 18 Heptalysis Analysis: Global Acquired Hemophilia Treatment Market
Figure 19 Five Whys Analysis
Figure 20 Global Acquired Hemophilia Treatment Market, By Type, 2021 Vs 2030, %
Figure 21 Global Acquired Hemophilia Treatment Market, By Treatment, 2021 Vs 2030, %
Figure 22 Global Acquired Hemophilia Treatment Market, By Therapeutic Areas, 2021 Vs 2030, %
Figure 23 Global Acquired Hemophilia Treatment Market, By End-User, 2021 Vs 2030, %
Figure 24 U.S. Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 25 Canada Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 26 Rest of North America Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 27 UK Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 28 Germany Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 29 Spain Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 30 Italy Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 31 France Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 32 Rest of Europe Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 33 China Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 34 Japan Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 35 India Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 36 Australia Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 37 South Korea Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 38 Rest of Asia Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 39 Brazil Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 40 Mexico Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 41 Rest of Latin America Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 42 GCC Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 43 Africa Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
Figure 44 Rest of Middle East and Africa Acquired Hemophilia Treatment Market (US$ Million), 2020-2030
List of Tables
Table 1 Global Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 2 Global Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 3 Global Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 4 Global Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 5 North America Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 6 North America Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 7 North America Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 8 North America Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 9 U.S. Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 10 U.S. Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 11 U.S. Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 12 U.S. Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 13 Canada Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 14 Canada Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 15 Canada Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 16 Canada Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 17 Rest of North America Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 18 Rest of North America Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 19 Rest of North America Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 20 Rest of North America Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 21 UK and European Union Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 22 UK and European Union Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 23 UK and European Union Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 24 UK and European Union Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 25 UK Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 26 UK Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 27 UK Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 28 UK Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 29 Germany Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 30 Germany Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 31 Germany Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 32 Germany Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 33 Spain Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 34 Spain Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 35 Spain Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 36 Spain Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 37 Italy Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 38 Italy Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 39 Italy Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 40 Italy Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 41 France Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 42 France Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 43 France Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 44 France Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 45 Rest of Europe Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 46 Rest of Europe Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 47 Rest of Europe Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 48 Rest of Europe Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 49 Asia Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 50 Asia Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 51 Asia Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 52 Asia Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 53 China Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 54 China Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 55 China Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 56 China Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 57 Japan Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 58 Japan Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 59 Japan Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 60 Japan Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 61 India Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 62 India Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 63 India Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 64 India Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 65 Australia Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 66 Australia Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 67 Australia Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 68 Australia Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 69 South Korea Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 70 South Korea Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 71 South Korea Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 72 South Korea Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 73 Latin America Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 74 Latin America Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 75 Latin America Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 76 Latin America Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 77 Brazil Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 78 Brazil Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 79 Brazil Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 80 Brazil Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 81 Mexico Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 82 Mexico Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 83 Mexico Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 84 Mexico Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 85 Rest of Latin America Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 86 Rest of Latin America Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 87 Rest of Latin America Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 88 Rest of Latin America Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 89 Middle East and Africa Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 90 Middle East and Africa Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 91 Middle East and Africa Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 92 Middle East and Africa Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 93 GCC Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 94 GCC Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 95 GCC Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 96 GCC Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 97 Africa Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 98 Africa Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 99 Africa Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 100 Africa Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)
Table 101 Rest of Middle East and Africa Acquired Hemophilia Treatment Market By Type, 2020-2030, USD (Million)
Table 102 Rest of Middle East and Africa Acquired Hemophilia Treatment Market By Treatment, 2020-2030, USD (Million)
Table 103 Rest of Middle East and Africa Acquired Hemophilia Treatment Market By Therapeutic Areas, 2020-2030, USD (Million)
Table 104 Rest of Middle East and Africa Acquired Hemophilia Treatment Market By End-User, 2020-2030, USD (Million)

Companies Mentioned

  • Baxter Healthcare Corporation
  • Biogen
  • Pfizer
  • F. Hoffman La Roche
  • Sanofi
  • Ferring Pharmaceuticals
  • Genentech Inc.
  • Bristol Myers Squibb
  • Novo Nordisk
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical
  • CSL Behring
  • Bayer AG